Renaissance Technologies
DSGN icon

Renaissance Technologies’s Design Therapeutics DSGN Stock Holding History

Renaissance Technologies’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.61M Sell
387,913
-20,287
-5% -$253K 0.01% 1397
2026
Q1 		$4.34M Buy
408,200
+121,100
+42% +$1.23M 0.01% 1458
2025
Q4 		$2.69M Buy
287,100
+12,800
+5% +$100K ﹤0.01% 1685
2025
Q3 		$2.07M Buy
274,300
+6,500
+2% +$32.6K ﹤0.01% 2049
2025
Q2 		$902K Buy
267,800
+2,800
+1% +$10.5K ﹤0.01% 2572
2025
Q1 		$1.02M Buy
265,000
+11,500
+5% +$54.9K ﹤0.01% 2416
2024
Q4 		$1.56M Sell
253,500
-20,500
-7% -$119K ﹤0.01% 2206
2024
Q3 		$1.47M Sell
274,000
-110,075
-29% -$518K ﹤0.01% 2220
2024
Q2 		$1.29M Sell
384,075
-69,325
-15% -$270K ﹤0.01% 2176
2024
Q1 		$1.83M Sell
453,400
-195,400
-30% -$522K ﹤0.01% 2090
2023
Q4 		$1.72M Buy
648,800
+484,600
+295% +$1.11M ﹤0.01% 2048
2023
Q3 		$388K Buy
164,200
+69,092
+73% +$322K ﹤0.01% 2829
2023
Q2 		$599K Sell
95,108
-6,643
-7% -$40.7K ﹤0.01% 2765
2023
Q1 		$587K Buy
+101,751
New +$761K ﹤0.01% 2794

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies's DSGN Position: Q2 2026 in Review

Renaissance Technologies reduced its Design Therapeutics (DSGN) stake by 5% in Q2 2026, selling an estimated $253K and leaving 387,913 shares worth $5.61M. The position accounts for 0.01% of the portfolio, ranked #1397.

Renaissance Technologies first reported a position in DSGN in Q1 2023 and has held it in 14 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Renaissance Technologies held 387,913 shares of Design Therapeutics worth $5.61M as of Q2 2026.
  • Renaissance Technologies sold 20,287 Design Therapeutics shares in Q2 2026, an estimated $253K.
  • Design Therapeutics made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1397 holding.
  • Renaissance Technologies first reported a position in Design Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.